Clinical Trial Update: Transtympanic STS Against Cisplatin-induced SNHL: the SOUND Trial [Phase 3]

View source ↗

Summary

Phase 3 SOUND trial is actively recruiting to evaluate transtympanic sodium thiosulfate for preventing cisplatin-induced sensorineural hearing loss.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cisplatin-induced Ototoxicity
• Sensorineural Hearing Loss

Drugs mentioned

• Sodium thiosulfate (sodium thiosulfate)

Snippet

Sponsor: The Netherlands Cancer Institute | Conditions: Cisplatin-related Hearing Loss | Phase 3 | Status: RECRUITING